- Teva Canada and Samsung Bioepis signed a licensing and commercialization agreement for Opuviz (aflibercept), a biosimilar referencing Eylea, in Canada.
- Under the deal, Samsung Bioepis will handle regulatory approval and manufacturing, while Teva Canada will lead commercialization.
- Opuviz, approved by Health Canada in October 2025, is indicated for wet AMD, DME, CRVO, BRVO, and mCNV.
- The partnership expands Teva’s biosimilars and ophthalmology portfolio while supporting broader access to affordable biologic eye treatments in Canada.
Takeaways
The Teva Canada–Samsung Bioepis deal makes Opuviz (aflibercept biosimilar to Eylea) a commercially available, lower‑cost alternative in Canada’s wet AMD, DME, and retinal vein occlusion markets, shifting the competitive dynamic from a single dominant biologic to at least one biosimilar with national distribution.
Source: CA Newswire
